Concord Drugs Ltd.
Fundamentals
- Market cap
- ₹101 cr
- P/E
- 95.40×
- ROE
- 0.99%
- Debt / equity
- 0.56
- 52-week range
- 29.55 — 92.52
Company snapshot
Concord Drugs Ltd.
Pharmaceuticals
₹100 cr
P/E 95.01×
Latest quarter · Mar 2026
Sales₹38 cr
Net profit₹1 cr
Op. margin+4.0%
EPS₹0.40
Strength & growth
Debt / equity0.56×
Current ratio1.56×
Sales CAGR+4.3%
EPS CAGR−17.1%
The timeline — 2 notes on Concord Drugs Ltd.
May 2026
- 27 May 26 · 4:37 PM IST Brief Brief · Earnings · Micro cap
Concord Drugs doubles revenue, auditor flags ₹4.14 cr overdue receivables
Audited FY26 standalone revenue rose to ₹75.85 cr, but the auditor's emphasis of matter on long-overdue receivables is the real story.
- 27 May 26 · 4:31 PM IST Brief Brief · Earnings · Micro cap
Concord Drugs doubled revenue. The auditor flagged ₹4.14 cr with no provision.
Standalone sales surged 105% to ₹75.85 cr in FY26. But the auditor won't sign off on ₹4.14 cr in receivables over two years old.